An open label, randomized clinical comparability study of the current liquid and commercial liquid formulations
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2012
At a glance
- Drugs Tremelimumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.
- 21 Jan 2008 Status changed from recruiting to in progress.
- 23 Oct 2007 Status changed from in progress to recruiting.